Market Newsdesk

ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO^® to Include Adults Aged 50 to 59 at Increased Risk of Disease

• Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74

NEW YORK–(BUSINESS WIRE)–
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes ABRYSVO^® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to 59 at increased risk of severe disease.

According to the CDC, between 15,000 – 20,000 RSV-associated hospitalizations occur annually in U.S. adults aged 50 – 59 years.¹ The risk of hospitalization is highest among those adults with one or more underlying medical conditions such as obesity, cardiovascular disease, diabetes, chronic obstructive pulmonary disorder (COPD), asthma, and other chronic or immunocompromising conditions.¹ With respect to ABRYSVO, ACIP stated:

• ACIP recommends adults 50–59 years of age who are at increased risk of severe RSV disease receive a single dose of RSV vaccine.

“With its vote to expand adult RSV vaccination recommendations, ACIP has taken an important step toward protecting individuals aged 50 to 59 who have underlying medical conditions that increase their risk for severe RSV illness,” said Alejandro Cane, Vice President, Vaccines and Antivirals U.S. Medical Lead, Pfizer. “We are proud that ABRYSVO has the broadest indication among RSV vaccines, covering older adults, adults 18 and older at heightened risk of severe disease, and pregnant women to help protect infants.”

The updated ACIP recommendation, which lowers the recommended age for RSV vaccination from 60 to 50 for high-risk adults, is pending final approval by the director of the CDC and the Department of Health and Human Services.

ABOUT RSV

Respiratory syncytial virus (RSV) is a contagious virus and a common cause of respiratory illness.² The virus can affect the lungs and breathing passages of an infected individual, potentially causing severe illness or death.^3,4 Chronic cardiovascular disease, chronic lung disease, moderate or severe immune compromise, diabetes with complications, and severe obesity are among the conditions that increase an individual’s risk for severe RSV.⁵ There are two major subgroups of RSV: RSV-A and RSV-B. Both subgroups cause disease and can co-circulate or alternate predominance from season to season.

ABOUT ABRYSVO

Pfizer currently is the only company with an RSV vaccine to help protect adults aged 60 and older, and adults 18 and older at increased risk of lower respiratory tract disease caused by RSV (RSV-LRTD), as well as infants through maternal immunization. ABRYSVO is an unadjuvanted, bivalent vaccine that was designed to provide broad protection against RSV-LRTD, regardless of the virus subgroup. In the prefusion state, the RSV fusion protein (F) is a major target of neutralizing antibodies, serving as the basis of Pfizer’s RSV vaccine. Variations in the F protein sequence among RSV-A and RSV-B subgroups are clustered in a key antigenic site, a target for potent neutralizing antibodies.

In May 2023, the FDA approved ABRYSVO for the prevention of LRTD caused by RSV in individuals 60 years of age or older. In June 2024, the Advisory Committee on Immunization Practices (ACIP) voted to update its recommendation of RSV vaccines for use in adults aged ≥75 years and adults age 60-74 years who are increased risk for severe RSV disease. In August 2023, the FDA approved ABRYSVO for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to 6 months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age. This was followed in September 2023 with ACIP’s recommendation for maternal immunization to help protect newborns from RSV seasonally where the vaccine should be administered from September through January in most of the continental United States.

Also in August 2023, Pfizer announced that the European Commission granted marketing authorization for ABRYSVO for both older adults and maternal immunization to help protect infants, and in March 2025 announced the amended marketing authorization to extend the indication to include a broader adult population. Additionally, ABRYSVO has received approvals for both indications in multiple countries worldwide.

INDICATIONS FOR ABRYSVO

ABRYSVO^® is a vaccine indicated in the U.S. for:

• the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in people 60 years of age and older
• the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV
• pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age

IMPORTANT SAFETY INFORMATION FOR ABRYSVO

• ABRYSVO should not be given to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any of its components
• An increased risk of Guillain-Barré syndrome (severe muscle weakness) was observed after vaccination with ABRYSVO
• For pregnant individuals: to avoid the potential risk of preterm birth, ABRYSVO should be given during 32 through 36 weeks gestational age
• Fainting can happen after getting injectable vaccines, including ABRYSVO. Precautions should be taken to avoid falling and injury during fainting
• Adults with weakened immune systems, including those receiving medicines that suppress the immune system, may have a reduced immune response to ABRYSVO
• Vaccination with ABRYSVO may not protect all people
• In adults 60 years of age and older, the most common side effects (≥10%) were fatigue, headache, pain at the injection site, and muscle pain
• In adults 18 through 59 years of age, the most common side effects (≥10%) were pain at the injection site, muscle pain, joint pain and nausea
• In pregnant individuals, the most common side effects (≥10%) were pain at the injection site, headache, muscle pain, and nausea
• In clinical trials where ABRYSVO was compared to placebo, infants born to pregnant individuals experienced low birth weight (5.1% ABRYSVO versus 4.4% placebo) and jaundice (7.2% ABRYSVO versus 6.7% placebo)

View the full ABRYSVO Prescribing Information.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

DISCLOSURE NOTICE:

The information contained in this release is as of April 16, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about ABRYSVO, including its potential benefits and a vote by ACIP to expand its recommendation to include adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of ABRYSVO; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when biologic license applications may be filed in particular jurisdictions for ABRYSVO for any potential indications; whether and when any applications that may be pending or filed for ABRYSVO may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether ABRYSVO for any such indications will be commercially successful; intellectual property and other litigation; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of ABRYSVO; uncertainties regarding the ability to obtain or maintain recommendations from vaccine advisory or technical committees and other public health authorities regarding ABRYSVO and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on our business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

____________________

¹ U.S. Centers for Disease Control and Prevention. “Evidence to Recommendations Framework (EtR): RSV Vaccination in Adults Aged 50–59 years” https://www.cdc.gov/acip/downloads/slides-2025-04-15-16/06-Melgar-Surie-adult-rsv-508.pdf Presented April 16, 2025. Accessed April 2025.

² World Health Organization. Respiratory Syncytial Virus (RSV) disease. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccine-standardization/respiratory-syncytial-virus-disease. Accessed February 2025.

³ U.S. Centers for Disease Control and Prevention. How RSV Spreads. https://www.cdc.gov/rsv/causes/index.html. Updated August 30, 2024. Accessed February 2025.

⁴ U.S. Centers for Disease Control and Prevention. RSV in Older Adults. https://www.cdc.gov/rsv/older-adults/index.html. Updated August 30, 2024. Accessed February 2025.

⁵ U.S. Centers for Disease Control and Prevention. Clinical Overview of RSV. https://www.cdc.gov/rsv/hcp/clinical-overview/index.html. Updated August 30, 2024. Accessed February 2025.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250416881933/en/

Media Contact:

[email protected]

+1 (212) 733-1226

Investor Contact:

[email protected]

+1 (212) 733-4848

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: FDA Health Infectious Diseases General Health Pharmaceutical Biotechnology

MEDIA:

Logo

Hess Midstream LP Schedules Earnings Release Conference Call

HOUSTON–(BUSINESS WIRE)–
Hess Midstream LP (NYSE: HESM) (“Hess Midstream”) announced today that it will hold a conference call on Wednesday, April 30, 2025, at 12:00 p.m. Eastern Time to discuss its first quarter 2025 earnings release.

To phone into the conference call, participants should register in advance using this link to receive a unique PIN and dial-in number. This conference call and subsequent replay will also be accessible by webcast (audio only) on Hess Midstream’s website at www.hessmidstream.com.

About Hess Midstream

Hess Midstream is a fee-based, growth-oriented, midstream company that owns, operates, develops and acquires a diverse set of midstream assets to provide services to Hess and third-party customers. Hess Midstream owns oil, gas and produced water handling assets that are primarily located in the Bakken and Three Forks Shale plays in the Williston Basin area of North Dakota. More information is available at www.hessmidstream.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of the federal securities laws. Generally, the words “anticipate,” “estimate,” “expect,” “forecast,” “guidance,” “could,” “may,” “should,” “believe,” “intend,” “project,” “plan,” “predict,” “will” and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results and current projections or expectations. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in the filings made by Hess Midstream with the U.S. Securities and Exchange Commission, which are available to the public. Hess Midstream undertakes no obligation to, and does not intend to, update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250416047113/en/

Investor Contact:

Jennifer Gordon

(212) 536-8244

Media Contact:

Lorrie Hecker

(212) 536-8250

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Energy Utilities Oil/Gas

MEDIA:

Logo

Fair Isaac Corporation Announces Date for Reporting of Second Quarter Fiscal 2025 Financial Results

BOZEMAN, Mont.–(BUSINESS WIRE)–
Global analytics software leader, FICO, will announce its second quarter fiscal 2025 results on April 29, 2025, after the market closes and will host a conference call on April 29^th at 5:00 p.m. Eastern time (4:00 p.m. Central/ 2:00 p.m. Pacific).

This call will be webcast and can be accessed at FICO’s website at www.fico.com/investors. A replay of the webcast will be available at our Event Calendar under Past Events through April 29, 2026.

About FICO

FICO (NYSE: FICO) powers decisions that help people and businesses around the world prosper. Founded in 1956, the company is a pioneer in the use of predictive analytics and data science to improve operational decisions. FICO holds more than 200 US and foreign patents on technologies that increase profitability, customer satisfaction and growth for businesses in financial services, insurance, telecommunications, health care, retail and many other industries. Using FICO solutions, businesses in more than 80 countries do everything from protecting four billion payment cards from fraud, to improving financial inclusion, to increasing supply chain resiliency. The FICO® Score, used by 90% of top US lenders, is the standard measure of consumer credit risk in the US and has been made available in over 40 other countries, improving risk management, credit access and transparency.

Learn more at https://www.fico.com/en

Join the conversation at https://x.com/FICO_corp & https://www.fico.com/blogs/

For FICO news and media resources, visit https://www.fico.com/en/newsroom

FICO is a registered trademark of Fair Isaac Corporation in the U.S. and other countries.

Statement Concerning Forward-Looking Information

Except for historical information contained herein, the statements contained in this news release that relate to FICO or its business are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the impact of COVID-19 on macroeconomic conditions and FICO’s business, operations and personnel, the success of the Company’s Decision Management strategy and reengineering initiative, the maintenance of its existing relationships and ability to create new relationships with customers and key alliance partners, its ability to continue to develop new and enhanced products and services, its ability to recruit and retain key technical and managerial personnel, competition, regulatory changes applicable to the use of consumer credit and other data, the failure to protect such data, the failure to realize the anticipated benefits of any acquisitions, or divestitures, and material adverse developments in global economic conditions or in the markets we serve. Additional information on these risks and uncertainties and other factors that could affect FICO’s future results are described from time to time in FICO’s SEC reports, including its Annual Report on Form 10-K for the year ended September 30, 2024 and its subsequent filings with the SEC. If any of these risks or uncertainties materializes, FICO’s results could differ materially from its expectations. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. FICO disclaims any intent or obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250416985955/en/

Investors & Analysts:

Dave Singleton

Fair Isaac Corporation

(800) 459-7125

[email protected]

KEYWORDS: United States North America Montana

INDUSTRY KEYWORDS: Data Analytics Data Management Professional Services Technology Software

MEDIA:

Logo

Xylem Announces Participation at Upcoming Investor Conferences

WASHINGTON–(BUSINESS WIRE)–
Xylem Inc. (NYSE: XYL), a leading global water solutions company that empowers customers and communities to build a more water-secure world, announced today that it will participate in the following upcoming conferences:

• Oppenheimer Industrials Conference, May 5, Virtual – Management and Investor Relations will present and participate in investor meetings.
• Stifel Industrials Conference, June 4, Boston – Management and Investor Relations will present and participate in investor meetings.

About Xylem

Xylem (XYL) is a Fortune 500 leading global water solutions company that empowers customers and communities to build a more water-secure world. Our 23,000 diverse employees delivered revenue of $8.6 billion in 2024, optimizing water and resource management with innovation and expertise. Join us at www.xylem.com and let’s solve water.

Xylem uses our Investor Relations website, www.xylem.com/en-us/investors, as a means of disclosing information which may be of interest or material to our investors and for complying with disclosure obligations under Regulation FD. Accordingly, investors should monitor our Investor Relations website, in addition to following our press releases, SEC filings, public conference calls, webcasts, and social media.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250416690859/en/

Media

Houston Spencer +1 (914) 240-3046

[email protected]

Investors

Keith Buettner +1 (724) 772-1531

[email protected]

KEYWORDS: United States North America District of Columbia

INDUSTRY KEYWORDS: Utilities Natural Resources Finance Energy Professional Services Technology Other Natural Resources Other Technology

MEDIA:

Logo

Luxfer Announces Date of First Quarter 2025 Earnings Conference Call

MILWAUKEE–(BUSINESS WIRE)–Luxfer Holdings PLC (NYSE: LXFR) (“Luxfer” or the “Company”), a global industrial company innovating niche applications in materials engineering, today announced the following details for its first quarter 2025 conference call.

Date and time:		Wednesday April 30, 2025, at 8:30 a.m. Eastern Time
Luxfer participants:		Andy Butcher		Chief Executive Officer
		Steve Webster		Chief Financial Officer
		Kevin Grant		Vice President of Investor Relations and Business Development
Dial-in registration:		United States or Canada: 800-274-8461
		International: (+1) 203-518-9814
		Conference ID: LXFRQ125
		Please dial into the call 15 minutes prior to the start time.
Webcast:		The earnings conference call webcast may be accessed by clicking on this link Q1 2025 Earnings Webcast
Replay:		Available from April 30, 2025, until May 14, 2025
Replay numbers:		United States or Canada: 800-839-2382
		International: (+1) 402-220-7201
Webcast replay:		Available on Luxfer’s Investor website at Luxfer.com at 4:30 p.m. Eastern Time, Wednesday, April 30, 2025.
Presentation material:		Earnings presentation material can be accessed through the Investors section at Luxfer.com

About Luxfer Holdings PLC

Luxfer (NYSE: LXFR) is a global industrial company innovating niche applications in materials engineering. Using its broad array of proprietary technologies, Luxfer focuses on value creation, customer satisfaction, and demanding applications where technical know-how and manufacturing expertise combine to deliver a superior product. Luxfer’s high-performance materials, components, and high-pressure gas containment devices are used in defense and emergency response, clean energy, healthcare, transportation, and general industrial applications. For more information, please visit www.luxfer.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250416669835/en/

Kevin Cornelius Grant

Vice President of Investor Relations and Business Development

[email protected]

KEYWORDS: North America United States Ireland United Kingdom Europe Wisconsin

INDUSTRY KEYWORDS: Engineering Chemicals/Plastics Other Manufacturing Manufacturing

MEDIA:

Logo

Clearwater Analytics to Announce First Quarter 2025 Financial Results on April 30, 2025

BOISE, Idaho–(BUSINESS WIRE)–Clearwater Analytics Holdings, Inc. (NYSE: CWAN), (“Clearwater Analytics” or the “Company”), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, will release financial results for the first quarter ended March 31, 2025 after the U.S. financial markets close on Wednesday, April 30, 2025.

In conjunction with this announcement, Clearwater Analytics will host a conference call on April 30, 2025, at 5:00 p.m. ET through a live webcast available on the Company’s investor relations website. Participants must visit investors.clearwateranalytics.com in advance to register, download, and install any necessary audio software. A replay of the webcast will be available on the Company’s investor relations website, in addition to a press release related to the financial results, related financial tables, and the call transcript.

About Clearwater Analytics

Clearwater Analytics (NYSE: CWAN), a global, industry-leading SaaS solution, automates the entire investment lifecycle. With a single instance, multi-tenant architecture, Clearwater offers award-winning investment portfolio planning, performance reporting, data aggregation, reconciliation, accounting, compliance, risk, and order management. Each day, leading insurers, asset managers, corporations, and governments use Clearwater’s trusted data to drive efficient, scalable investing on more than $8.8 trillion in assets spanning traditional and alternative asset types. Additional information about Clearwater can be found at clearwateranalytics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250416858317/en/

Joon Park

Investor Relations

+1 415-906-9242

[email protected]

Claudia Cahill

Media Relations

+1 703-728-1221

[email protected]

KEYWORDS: United States North America Idaho

INDUSTRY KEYWORDS: Professional Services Data Management Data Analytics Technology Software Finance Asset Management

MEDIA:

Logo

Clearwater Analytics to Participate in Upcoming Investor Conferences in Second Quarter 2025

BOISE, Idaho–(BUSINESS WIRE)–Clearwater Analytics Holdings, Inc. (NYSE: CWAN), (“Clearwater Analytics” or the “Company”), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, today announced that members of its executive leadership team will be participating in the following investor conferences in the second quarter of 2025.

Clearwater Analytics Chief Executive Officer Sandeep Sahai will join a fireside chat and participate in one-on-one meetings at the J.P. Morgan 53rd Annual Global Technology, Media and Communications Conference in Boston on Wednesday, May 14, 2025.

Clearwater Analytics Chief Financial Officer Jim Cox will join a fireside chat and participate in one-on-one meetings at the William Blair 45th Annual Growth Stock Conference in Chicago on Wednesday, June 4, 2025.

Mr. Cox will present at the Oppenheimer’s Annual Software Bus Tour in Santa Clara, CA on Tuesday, June 10, 2025.

Mr. Sahai will join a fireside chat and participate in one-on-one meetings at the Morgan Stanley US Financials Conference in New York City on Wednesday, June 11, 2025.

Mr. Cox will join a fireside chat and participate in one-on-one meetings at the D.A. Davidson 1st Annual Consumer & Technology Conference in Nashville, TN on Wednesday, June 11, 2025.

Webcasts from the fireside chats will be made available on Clearwater Analytics’ investor relations website at investors.clearwateranalytics.com.

About Clearwater Analytics

Clearwater Analytics (NYSE: CWAN), a global, industry-leading SaaS solution, automates the entire investment lifecycle. With a single instance, multi-tenant architecture, Clearwater offers award-winning investment portfolio planning, performance reporting, data aggregation, reconciliation, accounting, compliance, risk, and order management. Each day, leading insurers, asset managers, corporations, and governments use Clearwater’s trusted data to drive efficient, scalable investing on more than $8.8 trillion in assets spanning traditional and alternative asset types. Additional information about Clearwater can be found at clearwateranalytics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250416462685/en/

Joon Park

Investor Relations

+1 415-906-9242

[email protected]

Claudia Cahill

Media Relations

+1 703-728-1221

[email protected]

KEYWORDS: United States North America Idaho

INDUSTRY KEYWORDS: Professional Services Data Management Data Analytics Technology Software Finance Asset Management

MEDIA:

Logo